developed to predict the chemotherapeutic response of tumours prior to initiation of individualized treatment for breast cancer. This study investigated whether the in vitro chemosensitivity response of cell lines derived from breast cancer patients was affected by HER2/neu expression. We cultured breast cancer cell lines from 50 patients and the adenosine triphosphatebased chemotherapy response assay (ATP-CRA) was performed with 5-fluorouracil, gemcitabine, docetaxel, doxorubicin, methotrexate, vinorelbine and paclitaxel. (7.3 -65.7% ). In addition, gemcitabine showed significantly greater activity in HER2/neupositive patients. In contrast, docetaxel was significantly less effective in HER2/neu-positive patients. No significant correlation was found between the other agents and HER2/neu expression. The use of the ATP-CRA test for metastatic tissue from patients with recurrent disease might be a useful approach to determine the most effective chemotherapy regimen.
Introduction
Chemotherapy is an established therapeutic modality for the treatment of breast cancer patients, however the empirical use of standard chemotherapy regimens is not based on the biology of the tumour to be treated. When considering adjuvant chemotherapy, therefore, it is difficult to predict the chemosensitivity of the tumour in individual patients. Many investigators have focused on in vitro chemosensitivity testing to determine an effective chemotherapeutic approach to the treatment of individual patients before the initiation of treatment. 1, 2 The objective response rate achieved by chemotherapy in advanced breast cancer is in the range of 40 -60%, 3 and the anthracyclines and taxanes are among the SU Woo, JW Bae, HG Kim et al. Chemosensitivity of breast cancer most effective agents. 3, 4 The ability to tailor treatment regimens by eliminating those agents found to be inactive in vitro, prior to therapy administration, would potentially avoid unnecessary toxicity, save time and avoid the medical costs associated with using an ineffective treatment. 5 Overexpression of HER2/neu is known to predict a poor outcome for adjuvant treatment. 6, 7 Although predicting the cytotoxic effects of anticancer agents before chemotherapy is administered has been reported, there is controversy about the clinical application of this strategy and, moreover, little is known about the correlation between in vitro chemosensitivity and prognosis in breast cancer patients. 8, 9 The aim of the current study was to evaluate whether the in vitro chemosensitivity of breast tumours is associated with HER2/neu expression in breast cancer patients.
Patients and methods

STUDY POPULATION
Female breast cancer patients that underwent optimal treatment for breast cancer at the Korea University Anam Hospital (Seoul, Korea) were enrolled in the study. The study was approved by the Institutional Review Board of Korea University Anam Hospital, and written informed consent was obtained from all enrolled patients.
Specimens of breast tumour tissue were obtained from paraffin-embedded blocks for each of the breast cancer patients. Clinical data from the medical records were reviewed to identify clinical features, pathological characteristics and biological makers. A positive expression of HER2/neu was determined by primary immunohistochemical staining with a score of 3+ (see below). In cases that demonstrated an immunohistochemical staining score of 2+, additional fluorescence in situ hybridization was performed.
IMMUNOHISTOCHEMICAL STAINING AND FLUORESCENCE IN SITU HYBRIDIZATION OF HER2/NEU
Immunohistochemical staining was carried out using monoclonal antibodies for the HER2/neu oncoprotein (CB11; dilution 1:400) with an automated autostainer (Dako, Glostrup, Denmark). HER2/neu immunostaining was scored from 0 to 3+ according to the HerceptTest™ (Dako) scoring method for breast carcinoma performed using a kit and following the manufacturer's instructions.
CYTOTOXIC AGENTS
The cytotoxic drugs chosen for testing were those commonly used in the treatment of breast cancer. These included the antimetabolites, 5-fluoruracil (5-FU), methotrexate and gemcitabine, and the spindle-active agents, paclitaxel, docetaxel and vinorelbine. Doxorubicin, a topoisomerase IIα inhibitor, was also included.
The treated drug concentrations (TDC) for each agent were determined by a set of test experiments which exhibited a scattered distribution of cell death in each specimen. 10 The TDCs used were: 10 µg/ml 5-FU, 16.9 µg/ml gemcitabine, 3.7 µg/ml docetaxel, 1.5 µg/ml doxorubicin, 0.37 µg/ml methotrexate, 0.18 µg/ml vinorelbine and 8.5 µg/ml paclitaxel. Drugs were used in triplicate at ×0.2, ×1 and ×5 TDC.
ATP-CRA ASSAY
The adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was performed as previously described. 10 Briefly, tumour tissues were delivered to the laboratory from the hospital stored in Hank's buffered salt solution (HBSS; Gibco BRL, Rockville, MD, USA) containing 100 IU/ml penicillin (Sigma, St Louis, MO, USA), 100 SU Woo, JW Bae, HG Kim et al.
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µg/ml streptomycin (Sigma), 100 µg/ml gentamycin (Gibco BRL), 2.5 µg/ml amphotericin B (Gibco BRL), and 5% fetal bovine serum (FBS; Gibco BRL). The tumour tissues underwent washing, quantification and mincing, followed by incubation with extracellular matrix degrading enzymes such as dispase (Sigma), pronase (Sigma) and DNase (Sigma) at 37°C for 12 -16 h. The cells from the tumour tissues were harvested using a cell strainer (BD Falcon, Bedford, MA, USA). Cell suspensions were subjected to Ficoll (1.077g/ml) gradient centrifugation at 400 g for 15 min. An elimination process using anti-CD45 antibody conjugated magnetic beads (Miltenyi Biotech, Auburn, CA, USA) removed any normal cells. The separated tumour cells were diluted to 2000 -20 000 viable cells/100 µl using Iscove's Modified Dulbecco's Medium (IMDM; Gibco BRL) containing 10% FBS and then seeded in triplicate in a 96-well ultra low attachment (ULA) microplate (Costar, Cambridge, MA, USA). Then 100 µl of a cytotoxic agent (see previous section) was added to the seeded cells and they were cultured for 48 h in a CO 2 incubator.
After 48 h of treatment, the cells from the untreated control group and the treated groups were lysed by addition of cell extraction reagent (DCS Innovative Diagnostik-Systeme, Hamburg, Germany). The ATP in the cell lysate was reacted with luciferin and excess luciferase (Roche, Mannheim, Germany), after which the flash-type luminescence was measured using a Victor 3™ multilabel counter (Perkin Elmer, Boston, MA, USA). The percentage cell death was defined as the difference between the ATP levels from the treated and untreated cells, divided by the ATP level of the untreated cells at ×1 TDC. The chemosensitivity index was calculated as the sum of the percentage inhibition for all concentrations tested (300 -Σ% inhibition at ×0.2, ×1 and ×5 TDC). The intra-assay mean coefficient of inhibition (inhibition rate) was calculated from the mean of three measurements of the luminescence value for each specimen as:
× 100 Mean luminescence in untreated group Rank = 300 -Σ% inhibition at ×0.2, ×1.0 and ×5.0 TDC.
STATISTICAL ANALYSIS
The statistical significance of any differences observed for the expression of biological markers in response to different cytotoxic drugs was calculated using the χ 2 test. A P < 0.05 was considered statistically significant.
Results
Between July 2004 and April 2006, 54 patients (all female) underwent treatment for breast cancer at the Korea University Anam Hospital. Their mean age was 53.5 years (range 29 -86 years). Cancer cells were successfully cultured from 50 (92.6%) patients. Four were excluded because the tumour cells failed to grow to sufficient viable cell numbers in cell culture. The ATP-CRA was, therefore, performed on 50 cultured cell lines. Sixteen (32%) of the 50 patients had breast tumours that expressed the HER2/neu protein. The clinical, histological and biological features of these patients and their tumours are shown in Table 1 .
CHEMOSENSITIVITY OF BREAST CANCER CELLS BY ATP-CRA ASSAY
The cultured cell lines that were tested in the same serum-free medium demonstrated heterogeneous sensitivity to the different SU Woo, JW Bae, HG Kim et al.
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cytotoxic drugs evaluated by ATP-CRA. The list of agents that were tested and their corresponding results are presented in Table  2 . The success rates of the ATP-CRA in our cancer specimens ranged from 96% (48/50) to 100% (50/50), with an overall ATP-CRA success rate of 98.3%. The rate of cell death, for the same concentration of each chemotherapeutic agent, ranged from 0.0 to 88.5%. We found that 5-FU combined the narrowest range of cytotoxic effects (7.3 -65.7%) with a high median rate of cell death (32.4%). Docetaxel showed the lowest median rate of cell death (11.6%) and paclitaxel showed the widest range of cytotoxic effects (0 -88.5%). Calculated mean rank was best for 5-FU (3.04) and worst for docetaxel (5.71) ( Table 3) . Validation of the results by using three different concentrations of each anticancer agent (×0.2, ×1 and ×5 TDC) showed 5-FU to have a high mean assay value (35.2%) and the most consistent result (39/50 [78%]) ( Table  4 ). Heterogeneity of the chemosensitivity response of the breast cancer cell lines from each of the patients to each of the anticancer drugs tested is shown in Fig. 1 ; it shows a broad range of chemosensitivity responses to the same concentration of each anticancer drug.
Features
Number 
CORRELATION BETWEEN CHEMOSENSITIVITY AND HER2/NEU
Expression of the estrogen receptor and the HER2/neu protein was analysed to assess if there was any association between these biological markers and the cell lines' responses to the cytotoxic agents. There was no significant correlation between the response to the cytotoxic agents that we tested and the estrogen receptor status of the breast cancer cell lines. A response to gemcitabine was significantly correlated with expression of HER2/neu (P = 0.01). In contrast, docetaxel was significantly less effective in cell lines that were HER2/neupositive (P = 0.04). No significant correlations were found between the other agents and HER2/neu expression (Table 5 ).
Discussion
The development of chemotherapeutic agents has improved the survival of breast cancer patients. The degree of improved clinical outcomes, however, is modest and comparable across a range of standard chemotherapy regimens. 11, 12 Although adjuvant chemotherapy and hormone therapy significantly improve survival in early breast cancer patients, 13 a considerable number of women treated do not benefit from adjuvant therapy. Chemosensitivity tests reflect the diversity of the response of specific cancer patients to cytotoxic drugs. Cortaztar et al. 9 reviewed the potential efficacy of individualized chemotherapy based on in vitro drug sensitivity testing compared with empirical regimens in patients with cancer. They concluded that the response rates were better with in vitro selected chemotherapy regimens than with empirical regimens in clinical practice. The ATP-CRA assay is more accurate than other reported chemosensitivity tests, such as the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 14, 15 The advantages of ATP-CRA include the need for only a small amount of cancer tissue and the suppression or elimination of normal cells from tissue specimens. The success rates of the ATP-CRA in our cancer specimens ranged from 96% (48/50) to 100% (50/50), with an overall ATP-CRA success rate of 98.3%. These values are similar or superior to other reports. 16, 17 The best chemosensitivity index ranks were observed with 5-FU, vinorelbine, and methotrexate. The best mean value was observed with 5-FU, followed by vinorelbine, methotrexate, doxorubicin, gemcitabine, paclitaxel and docetaxel; however, all the results were very close to each other.
A biological marker for tumours that: (i) is able to predict the likelihood of a response to chemotherapy; or (ii) could help in the selection of an agent most likely be effective for an individual patient, would be helpful in supporting therapeutic decisions not only in the adjuvant setting but also for neoadjuvant and palliative chemotherapy. The clinical significance of biological markers, however, remains controversial.
Cytotoxic drug Biomarker
Valid Non-valid Mean of rank P-value In our analysis, gemcitabine was significantly more effective in cancer cell lines that expressed HER2/neu than in those cases that were negative for HER2/neu (P = 0.01). The HER2/neu gene plays an important role in human malignancies; it is amplified and/or overexpressed in approximately 30% of human breast cancers. 18 Our studies have shown a positive expression of HER2/neu in 32% of cases (Table 1 ) and this is consistent with previous reports. 18, 19 Amplification of HER2/neu expression in breast cancer cells is associated with clinical responsiveness to anthracyclin-containing chemotherapy. 20 Other investigators have, however, reported that the patient's response to adjuvant and neoadjuvant chemotherapy did not significantly correlate with HER2/neu expression and/or p53 expression as shown by immunohistochemical staining of the HER2/neu and p53 proteins. 21, 22 The role of HER2/neu in modulating chemosensitivity in breast cancer patients therefore remains controversial.
Pathological complete remission has been shown to be associated with a significantly (P < 0.001) better outcome regardless of hormone receptor status in breast cancer patients who receive primary chemotherapy; however, the rates were only 24% in hormone receptor-negative tumours and 8% in hormone receptor-positive tumours. 23 Takamura et al. 24 did not find a significant association between the expression of biological markers, including HER2/neu, p53, MIB-1 and estrogen receptor-α (ER-α), and the response to cyclophosphamide and epirubicin therapy. Our results showed no significant correlation between the response to the cytotoxic agents that we tested and the estrogen receptor status of the breast cancer cell lines. Although our study comprised a relatively small sample size, we have planned a randomized double-blind prospective study based on these preliminary data.
In conclusion, the chemosensitivity response to a range of anticancer agents was found to vary depending on the breast cancer specimen. In general, the standard chemotherapeutic agents, 5-FU, vinorelbine, methotrexate and doxorubicin, were more cytotoxic in vitro than the secondary chemotherapeutic agents. In the breast cancer cell lines in this study, there was a significant association between HER2/neu expression and the efficacy of gemcitabine in the in vitro assay. The in vitro assessment of chemotherapeutic agents, prior to treatment, may be particularly useful in patients with recurrent metastatic disease. After standard chemotherapeutic treatment, we recommend testing metastatic tissue using an effective in vitro assay to select the most effective agent for optimal treatment. A larger prospective study is required to validate these preliminary findings.
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